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Abstract
The implementation of the seven-valent pneumococcal conjugate vaccine, PCV7, has resulted in signiﬁcant changes in the pneumococcal
population being carried and causing disease. We aimed to determine the invasive disease potential of serotypes causing invasive paediatric
disease in the era of conjugate vaccines in Catalonia, Spain, and their potential coverage by the 13-valent pneumococcal conjugate vaccine,
PCV13. As a secondary objective, we evaluated whether implementation of PCV7 had resulted in signiﬁcant changes in the invasive disease
potential of the most frequent serotypes circulating in the area. Two pneumococcal collections obtained from children admitted to the
University Hospital Sant Joan de Deu (Barcelona, Spain) between 2007 and 2011 were compared: a ﬁrst set of 159 invasive disease isolates,
and a second set of 209 nasopharyngeal isolates recovered from healthy children admitted for minor surgery. The most common invasive
serotypes were 1 (24.5%, n = 39), 19A (21.2%, n = 34), 5 (8.8%, n = 14), 7F (8.8%, n = 14) and 3 (5%, n = 8). The most common serotypes
in carriage were 19A (10%, n = 21), 6C (9%, n = 19), 23B (8.1%, n = 17), 6A (7.6%, n = 16) and 19F (6.2%, n = 13). A signiﬁcantly higher
propensity to cause invasive disease was observed for serotypes 1, 3, 5, 7F and 19A, all of which are included in PCV13. After
false-discovery-rate correction, the results were robust for serotypes 1, 5, 7F and 19A. Non-PCV13 serotypes had a low invasive disease
potential. Our data reinforce the need for continuous surveillance and should encourage efforts to introduce universal vaccination with
PCV13 in children in our region.
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Introduction
Streptococcus pneumoniae is a major cause of invasive disease
in children and a common cause of pneumonia, meningitis
and sepsis [1]. Despite being such a virulent pathogen, the
main ecological niche of the pneumococcus is the naso-
pharynx of healthy children, which is colonized asymptom-
atically [2]. Although almost all children carry pneumococci
during early childhood, very few develop disease. The
capsule of the pneumococcus has been considered its main
virulence factor and at least 94 serotypes have been
described [3]. Despite this diversity, a relatively small
number of serotypes are associated with most invasive
disease worldwide [4].
Recent epidemiological studies in different countries have
compared nasopharyngeal carriage rates of serotypes with
rates of invasive pneumococcal disease (IPD) to estimate the
invasive disease potential of individual serotypes and clones.
The results have shown that the potential to cause invasive
disease differs by serotype (and even by genotype). For
example, serotypes 6B, 19F and 23F have a low disease
potential while serotypes 1, 7F and 14 have a high disease
potential [5–11].
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The seven-valent pneumococcal conjugate vaccine (PCV7),
has proven to be remarkably effective in reducing overall
carriage and disease caused by PCV7 vaccine serotypes, leading
to its virtual extinction in some regions [12,13]. As a result, in
countries where PCV7 has been extensively used, the popu-
lation and distribution of serotypes causing invasive disease and
detected in nasopharyngeal carriers has changed, potentially
affecting the invasive disease potential of speciﬁc serotypes.
In Spain, PCV7 was licensed in 2001, PCV10 in April 2009
and PCV13 in January 2010; however, in our community,
Catalonia, these vaccines are not subsidized by the Spanish
Public Health System. It is estimated that <50% of children of
our geographical area were vaccinated with PCV7 during the
period 2007–2009 [14].
The main goal of this study was to determine the invasive
disease potential of serotypes causing invasive paediatric
disease in the era of conjugate vaccines in Catalonia, Spain,
and evaluate its potential coverage by the most recent
conjugate vaccine. As a secondary objective we evaluated
whether implementation of PCV7 had resulted in signiﬁcant
changes in the invasive disease potential of the most frequent
serotypes circulating in the area.
Materials and Methods
Study design and sample collection
Two sample collections were compared. The ﬁrst included all
invasive pneumococcal isolates (n = 159) obtained from
children admitted to the University Hospital Sant Joan de
Deu (Barcelona, Spain) between 2007 and 2011. The second
collection (n = 209) included pneumococcal isolates obtained
from the nasopharynx of healthy children who attended for
minor surgical procedures in our hospital during the same time
period. IPD was deﬁned as the presence of clinical ﬁndings of
infection together with the isolation by culture of S. pneumo-
niae in blood, cerebrospinal ﬂuid or any other sterile ﬂuid. In
both collections, subjects were children up to 6 years old. The
mean ages of patients with IPD and carriers was 27 months
(SD 19.0) and 34 months (SD 17.7), respectively.
The University Hospital Sant Joan de Deu is a tertiary
teaching children’s hospital that annually captures ~ 19% of all
paediatric admissions recorded in Catalonia. This region has a
population of around 7 million people, of which 1.2 million are
<18 years of age [15].
Microbiological identiﬁcation, antimicrobial susceptibility and
serotyping
Pneumococcal strains were identiﬁed by standard microbio-
logical methods that included the optochin sensitivity test and
an antigenic test targeting the capsular polysaccharide (Slidex
pneumo-kit; BioMerieux, Marcy-l’Etolie, France). The MICs to
penicillin, cefotaxime, erythromycin, tetracycline, chloramphe-
nicol and levoﬂoxacin were determined by Etest (BioMerieux).
Antibiotic susceptibilities were deﬁned according to the break-
points of the European Committee on Antimicrobial Suscepti-
bility Testing (EUCAST) [16]. Multidrug resistance was deﬁned
as non-susceptibility to three or more antimicrobial agents.
Pneumococcal isolates were serotyped by the Quellung
reaction at the National Pneumococcal Reference Centre of
Majadahonda (Madrid, Spain). Since 2010, a fragment analysis
technique based on ﬂuorescent PCR and subsequent fragment
analysis by capillary electrophoresis that allows the detection
of 40 serotypes/serogroups (1, 2, 3, 4, 5, 6A/6B, 6C, 7C/(7B/
40), 7F/7A, 8, 9N/9L, 9V/9A, 10A, 10F/(10C/33C), 11A/11D,
12F/(12A/44/46), 13, 14, 15A/15F, 15B/15C, 16F, 17F, 18/(18A/
18B/18C/18F), 19A, 19F, 20, 21, 22F/22A, 23A, 23B, 23F, 24/
(24A/24B/24F), 31, 33F/(33A/37), 34, 35A/(35C/42), 35B, 35F/
47F, 38/25F, 39) has been implemented in our laboratory [17]
and the Quellung reaction has been used as a complementary
assay when the serotype cannot be determined by the
PCR-based method.
Statistical analysis
Simpson’s Index of Diversity was used to measure the
collections’ diversity through the website www.comparingpar-
titions.info [18].
The invasive disease potential of serotypes was estimated
using ORs with 95% CI, as described by Brueggeman et al. [5].
The equation used for calculations of ORs was OR = (ad)/(bc),
where a was the number of invasive X serotypes, b was the
number of carriage X serotypes, c was the number of invasive
non-X serotypes, and d was the number of carriage non-X
serotypes. An OR of 1 indicated that the serotype was equally
likely to be recovered from invasive disease and carriage,
whereas an OR >1 indicated an increased probability to cause
invasive disease. OR signiﬁcance was tested with the two-tailed
Fisher exact test, using a cut-off p value of ≤0.05 (two-tailed)
for all statistical analyses. The resulting p values were
corrected for multiple testing by controlling the false discovery
rate (FDR) to ≤0.05 through the Benjamini and Hochberg
method as previously described [9,19].
Results
Serotype distribution in disease and colonization
Among the 159 pneumococcal strains causing IPD in young
children, collected in our laboratory between 2007 and 2011,
26 serotypes were identiﬁed. The most common were
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serotypes 1 (24.5%, n = 39), 19A (21.2%, n = 34), 5 (8.8%,
n = 14), 7F (8.8%, n = 14) and 3 (5%, n = 8). All of these
serotypes are included in the most recently approved pneu-
mococcal conjugate vaccine, PCV13. Overall, 13.8% (n = 22)
of the isolates were covered by PCV7, 55.9% (n = 89) were
covered by PCV10, and 84.9% (n = 135) were covered by
PCV13 (see Supplementary material, Table S1).
Among the 209 strains from carriage collected between
2007 and 2011, 37 serotypes were identiﬁed. The most
common were 19A (10%, n = 21), 6C (9%, n = 19), 23B (8.1%,
n = 17), 6A (7.6%, n = 16) and 19F (6.2%, n = 13). When
looking for the most common serotypes in invasive disease,
serotypes 1 and 3 (apart from 19A described above), were also
found among carriage strains (n = 2); serotypes 5 and 7F were
not detected. One strain was non-typeable. Overall, 14.3%
(n = 30) of the strains expressed serotypes included in PCV7,
15.3% (n = 32) expressed serotypes included in PCV10, and
33.9% (n = 71) expressed serotypes included in PCV13.
Comparison of the serotype diversity between the two
collections using the Simpson’s Index of Diversity, showed that
the invasive disease collection was signiﬁcantly less diverse
than the carriage collection: 0.874 (95% CI 0.844–0.904)
versus 0.953 (95% CI 0.945–0.962).
Antimicrobial susceptibility in disease and colonization
The percentage of penicillin non-susceptible strains according
to EUCAST penicillin breakpoints (≥0.12 mg/L) was similar in
both collections: 30.2% (n = 48) in the invasive collection and
28.2% (n = 59) in the carriers collection (p 0.7).
Multidrug resistance (MDR), deﬁned as non-susceptibility to
three or more antibiotics, was detected in 22.6% (n = 36) of
the invasive isolates and 17.7% (n = 37) of the carriage isolates
(p 0.2). Among the MDR invasive strains (n = 36), 21
expressed serotype 19A (58.3%) and four expressed serotype
19F (11.1%). Serotypes 6B, 15A, 16F and 24F were detected in
two strains each and serotypes 1, 23B and 24B in one strain
each. Among the MDR carrier strains (n = 37), 11 expressed
serotype 19A (29.7%), six expressed serotype 23A, ﬁve
serotype 19F, four serotype 23F and three serotype 15A.
Serotypes 6A and 6B were detected in two strains each, and
serotypes 6C, 16F, 24F and a non-typeable isolate were
detected in one strain each. Overall, among the MDR invasive
strains 80.6% expressed serotypes included in PCV13. The
corresponding percentage among carrier strains was signiﬁ-
cantly lower (54%, p 0.003).
Association with antimicrobial susceptibility proﬁle and
invasiveness
The putative association between antimicrobial resistance
and invasiveness was explored (Table 1). An apparent but
non-signiﬁcant association was found between penicillin
non-susceptibility and/or MDR strains and invasiveness.
Association of serotypes with invasiveness
There were signiﬁcant differences in the serotype-speciﬁc ORs
of the pneumococci characterized in this study (Table 2).
TABLE 1. Invasive disease potential according to antimicro-
bial susceptibility
Antimicrobial
susceptibility
No. of
invasive
isolates
(total: 159)
No. of
carriage
isolates
(total: 209) OR
95%
CI p value
Penicillin non-
susceptible strains
48 59 1.1 0.7–1.7 0.7
Multidrug-
resistant strainsa
36 37 1.3 0.8–2.3 0.2
aDeﬁned as non-susceptibility to three or more antimicrobial agents tested
(penicillin ≥0.12 mg/L, cefotaxime >0.5 mg/L, erythromycin >0.25 mg/L, tetracy-
cline ≥2 mg/L and cloramphenicol ≥8 mg/L).
TABLE 2. Invasive disease potential of serotypes
Serotypea
No. of isolates
ORb 95% CIb p valuecInvasive Carriage
PCV7 22 30 0.9 0.5–1.7 0.89
6B 2 4 0.6 0.1–3.7 0.71
14 6 4 2.0 0.5–8.2 0.47
19F 7 13 0.7 0.2–1.8 0.59
23F 4 7 0.7 0.2–2.6 0.69
Other PCV7d 3 2 – – –
PCV10 89 32 7.0 4.3–11.5 <0.01*
1 39 2 33.4 9.3–208.8 <0.01*
5 14 0 ∞ 5.9–∞ <0.01*
7F 14 0 ∞ 5.9–∞ <0.01*
PCV13 135 71 10.8 6.5–18.5 <0.01*
3 8 2 5.5 1.2–38.1 0.10
6A 4 16 0.3 0.1–0.9 0.12
19A 34 21 2.4 1.4–4.4 0.02*
Non PCV13 24 138 0.1 0.1–0.2 <0.01*
6C 1 19 0.1 0.003–0.4 <0.01*
10A 2 10 0.3 0.04–1.1 0.14
11A 0 9 0 0.0–0.5 0.03*
15A 2 6 0.4 0.1–2.1 0.45
15B 1 9 0.1 0.006–0.9 0.11
15C 2 4 0.7 0.1–3.7 0.71
16F 2 5 0.5 0.1–2.7 0.58
17F 0 5 0 0.1–1.1 0.15
21 0 5 0 0.1–1.1 0.15
22F 3 8 0.5 0.1–1.8 0.53
23A 0 9 0 0.0–0.5 0.03*
23B 5 17 0.4 0.1–1.0 0.14
34 0 6 0 0.0–0.8 0.11
35B 0 5 0 0.0–1.1 0.15
Otherd 6 21 – – –
Total 159 209
aPCV7: Serotypes included in 7-valent conjugate vaccine (4, 6B, 9V, 14, 18C, 19F
and 23F); PCV10: serotypes included in 10-valent conjugate vaccine (PCV7 plus
serotypes 1, 5, 7F); PCV13: serotypes included in 13-valent conjugate vaccine
(PCV10 plus serotypes 3, 6A, 19A); non-PCV13 serotypes: other serotypes not
included in any conjugate vaccine.
bOR and 95% CI are shown for serotypes that had at least ﬁve isolates. An OR >1
indicates increased invasive disease potential, and an OR <1 indicates decreased
invasive disease potential. ORs and 95% CIs in bold type are statistically signiﬁcant.
cp values that were signiﬁcant after false detection rate correction are marked by
asterisks.
dOther: serotypes with <5 isolates were (with the corresponding number of
isolates in disease and carriage, respectively): 4 (1/0), 8 (1/0), 9N (0/1), 9V (0/1),
11D (0/1), 12F (0/1), 13 (0/1), 18C (2/1), 24B (1/0), 24F (2/1), 28 (1/0), 29 (0/3), 31
(0/4), 33F (0/2), 35A (0/1), 35F (0/2), 37 (0/1), 38 (1/1), 47 (0/1), and NT (0/1).
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Serotypes 1, 3, 5, 7F and 19A, all included in the most recent
vaccine (PCV13), were associated with high invasiveness with
an OR signiﬁcantly higher than 1. These results were robust
after FDR correction for serotypes 1, 5, 7F and 19A. In
contrast, non-PCV13 serotypes were associated with low
invasive disease potential (overall, OR 0.1, 95% CI 0.1–0.2)
(Table 2). This was also noted for the recently described
serotype 6C (OR 0.1, 95% CI 0.003–0.4, p 0.001). Signiﬁcantly
low invasiveness of non-PCV13 serotypes was observed both
in children younger than 2 years old and in the older group
(Table 3).
Discussion
Since the implementation of PCV7, the rank order of the most
frequent serotypes causing IPD and being carried has changed
signiﬁcantly in Catalonia, Spain [15,20,21]. We aimed to
evaluate whether this has resulted in changes in the invasive
disease potential of the most frequent serotypes circulating in
the area.
The results of the present study showed that serotypes 1, 5,
7F and 19A, which became more prevalent in invasive disease
in Spain and Portugal during the last decade [22–24], have a
high invasive disease potential. Previous studies, conducted
before the introduction of conjugate vaccines, had also
identiﬁed these serotypes as highly invasive [5,6,10,25]. In
addition, the observation that, among serotype 19A, MDR
strains have expanded, is worrying [26]. These four serotypes
are now included in the most recent conjugate vaccine,
PCV13.
Of interest, the results obtained for serotype 3 suggested a
high invasive disease potential (OR 5.5, 95% CI 1.2–38.1,
p 0.02 before FDR correction). However, this result was not
signiﬁcant after FDR correction (p 0.10, Table 2), a statistical
test that has seldom been used in most published studies of
this nature and that aims to correct for the risk of detecting
signiﬁcant associations due to chance alone when multiple
comparisons are performed [9,19]. The invasive disease
potential of this serotype remains controversial. Bruegge-
mann et al., [6] in an extended meta-analysis that included
data of >4000 isolates from carriers and >700 isolates of
patients with IPD recruited in seven datasets, indicated that
serotype 3 had an OR signiﬁcantly <1 and, consequently, a
low propensity to cause invasive disease. Sa-Le~ao et al. [9] in
a study conducted during 2001–2003 in Portugal, Yildirim
et al. [27] in a study conducted during 2003–2009 in
Massachusetts and Rivera-Olivero et al. [28] in a study
conducted during 2006–2008 in Caracas associated serotype
3 with a high invasive disease potential. Of note, serotype 3
has become the third most frequent paediatric serotype in
children with IPD in Barcelona [29]. The reasons for these
contrasting ﬁndings may be multifactorial. For example, a
difference in the lineages associated with this serotype in each
study may be distinct. In fact, recent studies have shown that
apart from the serotype, the genotype may also affect the
disease potential of a lineage [9,10,30]. In addition, it is
conceivable that removal of serotypes included in PCV7 from
the pneumococcal population may have resulted in a com-
petitive release of some non-PCV7 serotypes. This could in
turn lead, ultimately, to changes in the invasive disease
potential of selected non-PCV7 serotypes [31]. Clearly,
further studies will be needed to fully address these
questions.
In our study, a low attack rate was observed in all
non-PCV13 serotypes, the recently described serotype 6C
among them. In recent years, serotype 6C has expanded,
becoming one of the most prevalent serotypes in carriage
among healthy children [32,33]. Nevertheless, this serotype
was a rare cause of IPD in our study. Given that serotype 6C
was not analysed in the pre-vaccine era, our data regarding
the low attack rate of this speciﬁc serotype are novel and of
interest.
In conclusion, we have found that all serotypes with high
attack rate are included in PCV13 and that the remaining
serotypes circulating in our regions have a low invasive disease
potential. Our data reinforce the need for continuous
surveillance and should encourage efforts to introduce
universal vaccination with PCV13 in children.
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TABLE 3. Invasive disease potential of non-PCV13 serotypes
according to age
Non-PCV13
serotypes
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